drugset / Trial / NCT02087397

Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction

NCT02087397 ↗

Phase 1/2 Withdrawn Ageless Regenerative Institute
NaSingle-groupOpen-labelTreatment

Summary

This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction cells (AD-SVF) implantation delivered into the corpus cavernous in patients with Erectile Dysfunction. The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed Erectile Dysfunction.

Timeline

Start
2014-03
Primary completion
2017-11
Completion
2017-12

Outcome

Outcome not reported

Stopped: “company dissolved”

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-SVF Cell therapy — Other

Indications